MEDICURE
About Us - Products In Development - Clinical Trials - Investor Relations - Latest News - Contact Us Contact Us Latest News Investor Relations Clinical Trials Products in Development About Us Medicure

May 11, 2006

MEDICURE TO PRESENT AT RODMAN & RENSHAW GLOBAL HEALTHCARE CONFERENCE

WINNIPEG, ManitobaÐ (May 11, 2006)

WINNIPEG, Manitoba– (May 11, 2006) Medicure Inc. (TSX:MPH; Amex: MCU), a cardiovascular drug discovery and development company, today announced it will make a corporate presentation at the Rodman & Renshaw 3 rd Annual Global Healthcare Conference in Monte Carlo, Monaco. On Monday, May 15, 2006, at 9:25AM local time (3:25AM Eastern), Albert D. Friesen, PhD, Medicure’s President and CEO, will deliver a corporate presentation in the Zaphyr Salon of Le Meridien Beach Plaza Hotel. The presentation will be webcast live and archived on the Medicure website.

Listen to webcast

About Medicure Inc.

Medicure Inc. is a cardiovascular drug discovery and development Company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine, the largest pharmaceutical market sector. The Company's solid position in this field is supported by the following attributes:

  • Cardiovascular focused pipeline: a global market of over US $70 billion
  • Two drugs - MC-1 & MC-4232 - in late stage clinical development
  • Four positive Phase II trials completed
  • FDA Fast Track designation for MC-1
  • Unique products addressing major, inadequately served markets
  • Dual action antithrombotic, MC-45308, with positive preclinical results

Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule, anti-ischemics, and antithrombotics towards human clinical studies.

This press release contains forward-looking statements that involve risks, which may cause actual results to differ materially from the statements made, and accordingly may be deemed to be forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such risks, include among others, those described in the Company’s annual return on Form 20-F. The forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

Derek Reimer
Chief Financial Officer

Hogan Mullally
Manager of Investor & Public Relations

Medicure Inc.
888-435-2220
204-488-9823 fax
info@medicure.com

Back to News Releases

News Archives

2006 Archives

2005 Archives

2004 Archives

2003 Archives


Legal - Privacy
For more information please email us: info@medicure.com